Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$0.61
+6.9%
$0.65
$0.50
$1.39
$35.74M1.4346,656 shs163,641 shs
RenovaCare Inc. stock logo
RCAR
RenovaCare
$0.00
$0.00
$0.00
N/A-129.861,458 shs1,725 shs
TELA Bio, Inc. stock logo
TELA
TELA Bio
$1.10
+11.1%
$0.75
$0.50
$2.20
$44.32M1.3244,769 shs163,914 shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$2.17
$2.16
$0.70
$3.44
$13.58M-1.11N/AN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
+6.93%-0.08%-0.07%-9.30%-30.97%
RenovaCare Inc. stock logo
RCAR
RenovaCare
0.00%0.00%0.00%0.00%+900.00%
TELA Bio, Inc. stock logo
TELA
TELA Bio
+11.11%+25.74%+59.42%+35.67%+15.79%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$0.61
+6.9%
$0.65
$0.50
$1.39
$35.74M1.4346,656 shs163,641 shs
RenovaCare Inc. stock logo
RCAR
RenovaCare
$0.00
$0.00
$0.00
N/A-129.861,458 shs1,725 shs
TELA Bio, Inc. stock logo
TELA
TELA Bio
$1.10
+11.1%
$0.75
$0.50
$2.20
$44.32M1.3244,769 shs163,914 shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$2.17
$2.16
$0.70
$3.44
$13.58M-1.11N/AN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
+6.93%-0.08%-0.07%-9.30%-30.97%
RenovaCare Inc. stock logo
RCAR
RenovaCare
0.00%0.00%0.00%0.00%+900.00%
TELA Bio, Inc. stock logo
TELA
TELA Bio
+11.11%+25.74%+59.42%+35.67%+15.79%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
2.00
Hold$5.38781.87% Upside
RenovaCare Inc. stock logo
RCAR
RenovaCare
0.00
N/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.40
Hold$2.20100.00% Upside
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TELA, CTSO, VAPO, and RCAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2026
TELA Bio, Inc. stock logo
TELA
TELA Bio
Reiterated RatingSell (E+)
4/8/2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
Reiterated RatingSell (E+)
3/27/2026
TELA Bio, Inc. stock logo
TELA
TELA Bio
Lower Price TargetMarket Outperform$5.00 ➝ $3.00
3/26/2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
Reiterated RatingBuy$10.00
3/25/2026
TELA Bio, Inc. stock logo
TELA
TELA Bio
Lower Price TargetNeutral$1.25 ➝ $1.00
3/25/2026
TELA Bio, Inc. stock logo
TELA
TELA Bio
Lower Price TargetBuy$3.00 ➝ $2.00
3/25/2026
TELA Bio, Inc. stock logo
TELA
TELA Bio
Lower Price TargetBuy$4.00 ➝ $2.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$37.06M1.03N/AN/A$0.09 per share6.77
RenovaCare Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
$80.28M0.61N/AN/A$0.16 per share6.88
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$68.67M0.20N/AN/A($9.01) per share-0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$8.20M-$0.13N/AN/AN/A-22.12%-150.53%-32.75%5/13/2026 (Estimated)
RenovaCare Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$38.83M-$0.83N/AN/AN/A-48.37%-433.58%-53.00%5/12/2026 (Estimated)
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$8.51N/AN/AN/A-76.74%N/A-68.08%N/A

Latest TELA, CTSO, VAPO, and RCAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.06N/AN/AN/A$9.40 millionN/A
5/12/2026Q1 2026
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.14N/AN/AN/A$18.60 millionN/A
3/25/2026Q4 2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.05-$0.09-$0.04-$0.09$9.22 million$9.23 million
3/24/2026Q4 2025
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.18-$0.16+$0.02-$0.17$21.04 million$20.87 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
RenovaCare Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
N/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
2.82
2.13
1.58
RenovaCare Inc. stock logo
RCAR
RenovaCare
N/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
8.82
4.20
3.59
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
0.25
0.09

Institutional Ownership

CompanyInstitutional Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
32.87%
RenovaCare Inc. stock logo
RCAR
RenovaCare
N/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
94.35%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%

Insider Ownership

CompanyInsider Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
7.30%
RenovaCare Inc. stock logo
RCAR
RenovaCare
0.86%
TELA Bio, Inc. stock logo
TELA
TELA Bio
4.70%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
22062.70 million58.12 millionOptionable
RenovaCare Inc. stock logo
RCAR
RenovaCare
1N/AN/ANot Optionable
TELA Bio, Inc. stock logo
TELA
TELA Bio
12044.77 million42.66 millionOptionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
2906.26 million5.27 millionNo Data

Recent News About These Companies

Vapotherm, Inc.: Vapotherm Announces Closing of Merger
Vapotherm Announces Closing of Merger
PLPL Plandaí Biotechnology, Inc.
VA20.SG,0P0001F4D7,0 (VA20.SG)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$0.61 +0.04 (+6.93%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$0.61 +0.00 (+0.25%)
As of 05/7/2026 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

RenovaCare stock logo

RenovaCare OTCMKTS:RCAR

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.

TELA Bio stock logo

TELA Bio NASDAQ:TELA

$1.10 +0.11 (+11.11%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$1.11 +0.01 (+0.91%)
As of 05/7/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Vapotherm stock logo

Vapotherm NYSE:VAPO

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.